SEARCH

SEARCH BY CITATION

References

  • 1
    Hsing AW, Rashid A, Devesa S, Fraumeni JF. Biliary tract cancer. In: SchottenfeldD, FraumeniJF,Jr, eds. Cancer Epidemiology and Prevention, 3rd ed. New York: Oxford University Press. 3rd ed. In press, 2005.
  • 2
    Hsing AW, Gao YT, Devesa SS, Jin F, Fraumeni JF,Jr. Rising incidence of biliary tract cancers in Shanghai, China. Int J Cancer 1998; 75: 36870.
  • 3
    Jin F, Devesa SS, Chow WH, Zheng W, Ji BT, Fraumeni JF,Jr, Gao YT. Cancer incidence trends in urban Shanghai, 1972–1994: an update. Int J Cancer 1999; 83: 43540.
  • 4
    Uhler ML, Marks JW, Judd HL. Estrogen replacement therapy and gallbladder disease in postmenopausal women. Menopause 2000; 7: 1627.
  • 5
    Heuman R, Larsson-Cohn U, Hammar M, Tiselius HG. Effects of postmenopausal ethinylestradiol treatment on gallbladder bile. Maturitas 1980; 2: 6972.
  • 6
    Vore M. Estrogen cholestasis. Membranes, metabolites, or receptors? Gastroenterology 1987; 93: 6439.
  • 7
    Zuber MX, Simpson ER, Waterman MR. Expression of bovine 17 α-hydroxylase cytochrome P-450 cDNA in nonsteroidogenic (COS 1) cells. Science 1986; 234: 125861.
  • 8
    Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 1997; 57: 10635.
  • 9
    Ambrosone CB, Moysich KB, Furberg H, Freudenheim JL, Bowman ED, Ahmed S, Graham S, Vena JE, Shields PG. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors. Breast Cancer Res 2003; 5: R4551.
  • 10
    Miyoshi Y, Ando A, Ooka M, Shiba E, Taguchi T, Tamaki Y, Noguchi S. Association of CYP17 genetic polymorphism with intra-tumoral estradiol concentrations but not with CYP17 messenger RNA levels in breast cancer tissue. Cancer Lett 2003; 195: 816.
  • 11
    Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, Lonning PE, Erikstein B, Karesen R, Gabrielsen OS, Borresen-Dale AL. CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res 1999; 59: 28258.
  • 12
    Lin CJ, Martens JW, Miller WL. NF-1C, Sp1, and Sp3 are essential for transcription of the human gene for P450c17 (steroid 17α-hydroxylase/17,20 lyase) in human adrenal NCI-H295A cells. Mol Endocrinol 2001; 15: 127793.
  • 13
    Feigelson HS, McKean-Cowdin R, Henderson BE. Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 2002; 17: 4456.
  • 14
    Ntais C, Polycarpou A, Ioannidis JP. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003; 12: 1206.
  • 15
    Haiman CA, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I. A polymorphism in CYP17 and endometrial cancer risk. Cancer Res 2001; 61: 395560.
  • 16
    McKean-Cowdin R, Feigelson HS, Pike MC, Coetzee GA, Kolonel LN, Henderson BE. Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. Cancer Res 2001; 61: 8489.
  • 17
    Wadelius M, Andersson AO, Johansson JE, Wadelius C, Rane E. Prostate cancer associated with CYP17 genotype. Pharmacogenetics 1999; 9: 6359.
  • 18
    Berstein LM, Imianitov EN, Gamaiunova VB, Kovalevskii AI, Kuligina ES, Belogubova EV, Buslov KG, Karpova MB, Togo AV, Volkov ON, Kovalenko IG, Chernobrovkina AE. Genetic polymorphism of steroid 17 α-hydroxylase/17,20-lyase (CYP17) and hyperinsulinemia in endometrial carcinoma. Vopr Onkol 2002; 48: 6738.
  • 19
    Madigan MP, Gao YT, Deng J, Pfeiffer RM, Chang BL, Zheng S, Meyers DA, Stanczyk FZ, Xu J, Hsing AW. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. Int J Cancer 2003; 107: 2714.
  • 20
    Ntais C, Polycarpou A, Tsatsoulis A. Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur J Endocrinol 2003; 149: 46977.
  • 21
    Rashid A, Gao YT, Bhakta S, Shen MC, Wang BS, Deng J, Fraumeni JF,Jr, Hsing AW. Beta-catenin mutations in biliary tract cancers: a population-based study in China. Cancer Res 2001; 61: 34069.
  • 22
    Liu E, Sakoda LC, Gao Y-T, Rashid A, Shen MC, Wang BS, Deng J, Han TQ, Zhang BE, Fraumeni JF,Jr, Hsing AW. Aspirin use and risk of biliary tract cancer: a population-based study in Shanghai, China. Cancer Epidemiol Biomarkers Prev 2005; 14: 13158.
  • 23
    Mori M, Saitoh S, Takagi S, Obara F, Ohnishi H, Akasaka H, Izumi H, Sakauchi F, Sonoda T, Nagata Y, Shimamoto K. A review of cohort studies on the association between history of diabetes mellitus and occurrence of cancer. Asian Pac J Cancer Prev 2000; 1: 26976.
  • 24
    Chapman BA, Wilson IR, Frampton CM, Chisholm RJ, Stewart NR, Eagar GM, Allan RB. Prevalence of gallbladder disease in diabetes mellitus. Dig Dis Sci 1996; 41: 22228.
  • 25
    Tavani A, Negri E, La Vecchia C. Menstrual and reproductive factors and biliary tract cancers. Eur J Cancer Prev 1996; 5: 2417.
  • 26
    Lambe M, Trichopoulos D, Hsieh CC, Ekbom A, Adami HO, Pavia M. Parity and cancers of the gall bladder and the extrahepatic bile ducts. Int J Cancer 1993; 54: 9414.
  • 27
    Moerman CJ, Berns MP, Bueno de Mesquita HB, Runia S. Reproductive history and cancer of the biliary tract in women. Int J Cancer 1994; 57: 14653.
  • 28
    Hosmer D, Lemenshow S. Applied logistic regression. New York: Wiley, 2000. Chapter 1, 1117.
  • 29
    Berstein LM, Imyanitov EN, Gamajunova VB, Kovalevskij AJ, Kuligina ESh, Belogubova EV, Buslov KG, Karpova MB, Togo AV, Volkov ON, Kovalenko IG. CYP17 genetic polymorphism in endometrial cancer: are only steroids involved? Cancer Lett 2002; 180: 4753.
  • 30
    Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Kelsey KT, Hunter DJ. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 1999; 59: 101520.
  • 31
    Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S. Genetic polymorphism in CYP17 and breast cancer risk in Japanese women. Eur J Cancer 2000; 36: 23759.
  • 32
    Ye Z, Parry JM. The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 2002; 17: 11926.
  • 33
    Spurdle AB, Hopper JL, Dite GS, Chen X, Cui J, McCredie MR, Giles GG, Southey MC, Venter DJ, Easton DF, Chenevix-Trench G. CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst 2000; 92: 167481.
  • 34
    Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Vainio H, Uusitupa M, Hirvonen A. Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 13438.
  • 35
    Habuchi T, Liqing Z, Suzuki T, Sasaki R, Tsuchiya N, Tachiki H, Shimoda N, Satoh S, Sato K, Kakehi Y, Kamoto T, Ogawa O, Kato T. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 2000; 60: 57103.
  • 36
    Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE. Cytochrome P450c17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998; 58: 5857.
  • 37
    Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994; 3: 18736.
  • 38
    Chang JH, Gertig DM, Chen X, Dite GS, Jenkins MA, Milne RL, Southey MC, McCredie MR, Giles GG, Chenevix-Trench G, Hopper JL, Spurdle AB. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study. Breast Cancer Res 2005; 7: R51321.
  • 39
    Everson GT, McKinley C, Lawson M, Johnson M, Kern F,Jr. Gallbladder function in the human female: effect of the ovulatory cycle, pregnancy, and contraceptive steroids. Gastroenterology 1982; 82: 7119.
  • 40
    Malik IA, Abbas Z, Shamsi Z, Daudi I, Shah HA, Moid I, Khan ZK, Shaikh H. Immuno-histochemical analysis of estrogen receptors on the malignant gallbladder tissue. J Pak Med Assoc 1998; 48: 1236.
  • 41
    Bhaskaran V. Hormonal receptors in carcinoma of the gallbladder. Trop Gastroenterol 2000; 21: 4850.
  • 42
    Kluft C, Leuven JA, Helmerhorst FM, Krans HM. Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment. Vascul Pharmacol 2002; 39: 14954.
  • 43
    Bruun JM, Nielsen CB, Pedersen SB, Flyvbjerg A, Richelsen B. Estrogen reduces pro-inflammatory cytokines in rodent adipose tissue: studies in vivo and in vitro. Horm Metab Res 2003; 35: 1426.
  • 44
    Dupont J, Karas M, LeRoith D. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components. J Biol Chem 2000; 275: 35893901.
  • 45
    Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee D. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 1999; 13: 78796.
  • 46
    Stewart AJ, Johnson MD, May FE, Westley BR. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 1990; 265: 211728.
  • 47
    Alvaro D, Alpini G, Onori P, Perego L, Svegliata Baroni G, Franchitto A, Baiocchi L, Glaser SS, Le Sage G, Folli F, Gaudio E. Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. Gastroenterology 2000; 119: 168191.
  • 48
    Erlinger S. Gallstones in obesity and weight loss. Eur J Gastroenterol Hepatol 2000; 12: 134752.
  • 49
    Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, Borch-Johnsen K, Olsen JH. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89: 13605.
  • 50
    Dowling RH. Review: pathogenesis of gallstones. Aliment Pharmacol Ther 2000; 14( suppl 2): 3947.
  • 51
    Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999; 20: 53582.
  • 52
    Stern MP. Strategies and prospects for finding insulin resistance genes. J Clin Invest 2000; 106: 3237.